
Crinetics shows Phase 2 success for atumelnant in reducing hormones and glucocorticoid use in CAH patients
Crinetics Pharmaceuticals presented positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist, showing it effectively lowers androgen levels and allows reduction of glucocorticoid doses in adults with classic congenital adrenal ...


